2024
Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource
Ito S, Pandya A, Hauser R, Krishnamurti L, Stites E, Tormey C, Krumholz H, Hendrickson J, Goshua G. Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource. American Journal Of Hematology 2024, 99: 570-576. PMID: 38279581, DOI: 10.1002/ajh.27211.Peer-Reviewed Original ResearchSickle cell diseaseDelayed hemolytic transfusion reactionQuality-adjusted life expectancyAlloimmunized patientsPatient populationRed blood cell alloimmunizationCell diseaseCost-effective interventionMedical expenditure of patientsHealth system perspectiveExpenditure of patientsIncremental cost-effectiveness ratioHemolytic transfusion reactionsUnited StatesMarkov cohort simulationCost-effectiveAverage patient populationCost-effectiveness ratioBirth cohortAnalytical time horizonAntibody historyCohort simulationTransfusionTransfusion reactionsLife expectancy
2001
Blood Transfusion in Elderly Patients with Acute Myocardial Infarction
Wu W, Rathore S, Wang Y, Radford M, Krumholz H. Blood Transfusion in Elderly Patients with Acute Myocardial Infarction. New England Journal Of Medicine 2001, 345: 1230-1236. PMID: 11680442, DOI: 10.1056/nejmoa010615.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionBlood transfusionMyocardial infarctionElderly patientsHematocrit valuesMortality rateLower short-term mortality rateMedicare beneficiaries 65 yearsShort-term mortality rateUse of transfusionsCoronary artery diseaseBeneficiaries 65 yearsDegree of anemiaLow hematocrit valuesArtery diseaseRetrospective studySubgroup analysisTransfusionPatientsAdmissionInfarctionMortalityHematocritAdverse effectsAnemia